Medios AG (MEDOF) AI Stock Analysis

Medios AG

(Other OTC:MEDOF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue GrowthThe exceptional top-line expansion indicates strong demand for specialty-pharmaceutical distribution and patient-specific therapy services. Sustained growth can improve scale, deepen pharmacy relationships, and create operating leverage if profitability improves.

Negative Factors

Very Thin ProfitabilityThin margins leave limited protection against supplier costs, pricing pressure, operating expenses, or unfavorable product mix. Even substantial revenue growth may therefore produce only modest earnings, constraining reinvestment and increasing earnings sensitivity.

Medios AG (MEDOF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.28B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 24.0
Beta (1Y): 0.45
Revenue Growth: 17.74%
EPS Growth: -34.02%
Country: US
Employees: 989
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Medios AG Business Overview & Revenue Model

Company Description

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies...

Medios AG Earnings Call Summary

Earnings Call Date:Nov 11, 2024(Q3-2024)|% Change Since:5.13%|Next Earnings Date:Jun 01, 2020

Earnings Call SentimentPositive

The earnings call reflects a positive sentiment with strong financial performance and strategic advancements, despite some challenges in specific segments and increased costs related to acquisitions.

Positive Updates

Record Q3 Performance

The company posted its best quarter ever with significant earnings growth. EBITDA pre margin reached 5% for the first time, driven by PST and Ceban.

Negative Updates

PST Segment Challenges

PST gross profit decreased due to deconsolidation of Kölsche Blister, regulatory headwinds, and increased performance-based payments.

Company Guidance

During the Q3 2024 earnings call for Medios AG, the company provided several key financial metrics and guidance highlights. The company achieved a revenue growth of more than 4% to EUR 1.4 billion for the first nine months of 2024, with a significant EBITDA pre increase of over 20% to EUR 55.8 million. The EBITDA pre margin reached the 5% mark for the first time, driven by strong performances in the PST and Ceban segments. Operational cash flow more than doubled to EUR 27.6 million, and the company confirmed its guidance for 2024, anticipating full-year revenues between EUR 1.9 billion and EUR 2.1 billion and an EBITDA pre in the range of EUR 82 million to EUR 91 million. The company also noted inorganic growth due to the acquisition of Ceban, contributing EUR 47.3 million in revenue and EUR 9.8 million in EBITDA pre for the period June through October 2024. Additionally, Medios is focusing on strategic priorities, including expanding operations into other European countries and entering the production of advanced therapies, with a commitment to maintaining high-quality personalized medicines.

Medios AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MEDOF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:M12	79Outperform	EUR 344.06M	17.94	16.58%	6.13%	-27.50%	13.64%
DE:LIK	67Neutral	EUR 153.00M	27.60	22.18%	1.96%	35.46%	17.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DE:MAK	47Neutral	EUR 18.98M	-1.39	16.80%	―	2.73%	-1.80%

* Healthcare Sector Average

Performance Comparison

MEDOF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MEDOF	Medios AG	17.43	3.36	23.88%
DE:MAK	MATERNUS-Kliniken AG	0.88	-0.18	-16.67%
DE:LIK	Limes Schlosskliniken AG	525.00	177.74	51.18%
DE:EIF	Eifelhoehen-Klinik AG	4.00	0.88	28.21%
DE:JTH0	Gesundheitswelt Chiemgau AG	11.40	-1.20	-9.52%
DE:M12	M1 Kliniken AG	19.14	5.44	39.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Medios AG AI Stock Analysis